JP2019527053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527053A5 JP2019527053A5 JP2019500261A JP2019500261A JP2019527053A5 JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5 JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019500261 A JP2019500261 A JP 2019500261A JP 2019527053 A5 JP2019527053 A5 JP 2019527053A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- sfgfr3
- growth factor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 97
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 25
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 24
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 206010053759 Growth retardation Diseases 0.000 claims description 17
- 231100000001 growth retardation Toxicity 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 230000009645 skeletal growth Effects 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 206010008723 Chondrodystrophy Diseases 0.000 claims description 8
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 8
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 claims description 8
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 8
- 208000008919 achondroplasia Diseases 0.000 claims description 8
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims description 8
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims description 8
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 6
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 claims description 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 206010058314 Dysplasia Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 210000004507 artificial chromosome Anatomy 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 210000004714 cranial suture Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 230000033001 locomotion Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 5
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 206010061159 Foot deformity Diseases 0.000 description 2
- 208000006358 Hand Deformities Diseases 0.000 description 2
- 208000007326 Muenke Syndrome Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 210000002532 foramen magnum Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022046573A JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359607P | 2016-07-07 | 2016-07-07 | |
| US62/359,607 | 2016-07-07 | ||
| US201762467478P | 2017-03-06 | 2017-03-06 | |
| US62/467,478 | 2017-03-06 | ||
| PCT/EP2017/067119 WO2018007597A1 (en) | 2016-07-07 | 2017-07-07 | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Division JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527053A JP2019527053A (ja) | 2019-09-26 |
| JP2019527053A5 true JP2019527053A5 (enExample) | 2020-08-20 |
| JP7046903B2 JP7046903B2 (ja) | 2022-04-04 |
Family
ID=59381265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500261A Active JP7046903B2 (ja) | 2016-07-07 | 2017-07-07 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046573A Active JP7348980B2 (ja) | 2016-07-07 | 2022-03-23 | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294289B2 (enExample) |
| EP (2) | EP4122955A1 (enExample) |
| JP (2) | JP7046903B2 (enExample) |
| KR (2) | KR102432192B1 (enExample) |
| CN (1) | CN109715658B (enExample) |
| AU (2) | AU2017294551B2 (enExample) |
| BR (1) | BR112019000257A2 (enExample) |
| CA (1) | CA3029877C (enExample) |
| DK (1) | DK3481859T3 (enExample) |
| ES (1) | ES2912559T3 (enExample) |
| HU (1) | HUE058734T2 (enExample) |
| IL (1) | IL264030A (enExample) |
| MX (1) | MX2018016257A (enExample) |
| PL (1) | PL3481859T3 (enExample) |
| PT (1) | PT3481859T (enExample) |
| RU (1) | RU2751483C2 (enExample) |
| SG (1) | SG11201900074WA (enExample) |
| SI (1) | SI3481859T1 (enExample) |
| WO (1) | WO2018007597A1 (enExample) |
| ZA (1) | ZA201900507B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| CA3076396A1 (en) * | 2017-09-20 | 2019-03-28 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
| WO2020243478A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Eye And Ear Infirmary | Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss |
| US11625937B2 (en) * | 2020-04-06 | 2023-04-11 | Toyota Motor Engineering & Manufacturing North America, Inc. | Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| DK0833620T3 (da) | 1995-06-12 | 2003-01-13 | Yeda Res & Dev | FGFR3, en markør for mesenkymale progenitorceller |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US20040109850A1 (en) | 2000-12-18 | 2004-06-10 | Neelam Jaiswal | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ATE533853T1 (de) | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| AU2010229994B2 (en) | 2009-03-25 | 2016-08-18 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
| US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| WO2011088196A2 (en) | 2010-01-14 | 2011-07-21 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| AU2013295805B2 (en) | 2012-07-24 | 2019-05-02 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| KR20150037876A (ko) | 2012-07-27 | 2015-04-08 | 제넨테크, 인크. | Fgfr3 관련 상태의 치료 방법 |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EA201591324A1 (ru) * | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| EP3242888B8 (en) * | 2015-01-07 | 2021-06-02 | Pfizer Inc. | Soluble fgfr3 decoys for treating skeletal growth disorders |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| CA3076396A1 (en) | 2017-09-20 | 2019-03-28 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
-
2017
- 2017-07-07 RU RU2019100381A patent/RU2751483C2/ru active
- 2017-07-07 SG SG11201900074WA patent/SG11201900074WA/en unknown
- 2017-07-07 HU HUE17742195A patent/HUE058734T2/hu unknown
- 2017-07-07 EP EP22167483.1A patent/EP4122955A1/en not_active Withdrawn
- 2017-07-07 PT PT177421955T patent/PT3481859T/pt unknown
- 2017-07-07 WO PCT/EP2017/067119 patent/WO2018007597A1/en not_active Ceased
- 2017-07-07 CN CN201780049433.8A patent/CN109715658B/zh not_active Expired - Fee Related
- 2017-07-07 AU AU2017294551A patent/AU2017294551B2/en not_active Ceased
- 2017-07-07 SI SI201731158T patent/SI3481859T1/sl unknown
- 2017-07-07 KR KR1020197002602A patent/KR102432192B1/ko active Active
- 2017-07-07 DK DK17742195.5T patent/DK3481859T3/da active
- 2017-07-07 CA CA3029877A patent/CA3029877C/en active Active
- 2017-07-07 ES ES17742195T patent/ES2912559T3/es active Active
- 2017-07-07 PL PL17742195T patent/PL3481859T3/pl unknown
- 2017-07-07 KR KR1020227027503A patent/KR20220122762A/ko not_active Ceased
- 2017-07-07 MX MX2018016257A patent/MX2018016257A/es unknown
- 2017-07-07 JP JP2019500261A patent/JP7046903B2/ja active Active
- 2017-07-07 EP EP17742195.5A patent/EP3481859B1/en active Active
- 2017-07-07 BR BR112019000257A patent/BR112019000257A2/pt not_active IP Right Cessation
-
2018
- 2018-04-02 US US15/943,436 patent/US10294289B2/en active Active
- 2018-12-30 IL IL264030A patent/IL264030A/en unknown
-
2019
- 2019-01-24 ZA ZA2019/00507A patent/ZA201900507B/en unknown
- 2019-05-20 US US16/417,174 patent/US11021528B2/en not_active Expired - Fee Related
-
2021
- 2021-04-20 US US17/234,841 patent/US11697678B2/en active Active
-
2022
- 2022-03-23 JP JP2022046573A patent/JP7348980B2/ja active Active
- 2022-05-02 AU AU2022202906A patent/AU2022202906A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527053A5 (enExample) | ||
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| RU2019100381A (ru) | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| ES2389697T3 (es) | Variantes de desintegrina y usos farmacéuticos de los mismos | |
| JP2017529059A5 (enExample) | ||
| JP2014534265A5 (enExample) | ||
| JP2016518351A5 (enExample) | ||
| EP3811967A1 (en) | Preparation of biologically active complexes | |
| CN112521514A (zh) | 一种蛋白复合物及其制备方法和应用 | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| AU2015356997A1 (en) | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases | |
| CN102552883B (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
| HUP0104126A2 (hu) | Gyógyszer a csontmetabolizmus hibáira | |
| CN101208106A (zh) | 癌症治疗剂 | |
| CA3133830A1 (en) | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins | |
| CN113355308A (zh) | 用于中和冠状病毒的人工多肽、制备方法及药物组合物 | |
| JPH07503705A (ja) | 医薬的リジン含有ポリペプチド組成物およびその使用法 | |
| WO1999065512A1 (fr) | Compositions medicinales contenant des peptides apparentes au facteur de croissance des fibroblastes | |
| JP2008509888A (ja) | 上皮成長因子受容体アンタゴニストおよび使用方法 | |
| JP4560612B2 (ja) | デコリン由来ペプチド | |
| JP2001523727A (ja) | 造血幹細胞を可動化する方法 |